14/04/2025 – AB Science today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with its lead compound masitinib, based on preclinical data Download PDF Post navigationPreviousPrevious post:Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick VermerschNextNext post:European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaRelated PostsEuropean Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaApril 23, 2025Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick VermerschMarch 4, 2025Summary of the webcast held on January 28, 2025January 29, 2025AB Science webcast of January 28, 2025January 29, 2025Live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CETJanuary 24, 2025AB Science will participate in the Biomed Forum investors conferenceJanuary 22, 2025
European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaApril 23, 2025
Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick VermerschMarch 4, 2025
